Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Platelet inhibition with cangrelor during PCI.

Wong BY.

N Engl J Med. 2013 Jul 25;369(4):393. doi: 10.1056/NEJMc1305978#SA1. No abstract available.

PMID:
23883388
2.

Platelet inhibition with cangrelor during PCI.

Bhatt DL, Harrington RA; CHAMPION PHOENIX Executive Committee and Investigators.

N Engl J Med. 2013 Jul 25;369(4):393-4. doi: 10.1056/NEJMc1305978. No abstract available.

3.

ACP Journal Club. Cangrelor reduced ischemic PCI complications more than clopidogrel without increasing severe bleeding.

Riezebos RK, Verheugt FW.

Ann Intern Med. 2013 Jun 18;158(12):JC5. doi: 10.7326/0003-4819-158-12-201306180-02005. No abstract available.

PMID:
23778929
4.

The duel between dual antiplatelet therapies.

Lange RA, Hillis LD.

N Engl J Med. 2013 Apr 4;368(14):1356-7. doi: 10.1056/NEJMe1302504. Epub 2013 Mar 10. No abstract available.

PMID:
23473370
5.

Effect of platelet inhibition with cangrelor during PCI on ischemic events.

Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA; CHAMPION PHOENIX Investigators.

N Engl J Med. 2013 Apr 4;368(14):1303-13. doi: 10.1056/NEJMoa1300815. Epub 2013 Mar 10.

6.

Platelet inhibition with cangrelor.

Ruparelia N, Spyrou N.

N Engl J Med. 2010 Mar 18;362(11):1048-9; author reply 1049. doi: 10.1056/NEJMc1001127. No abstract available.

7.

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.

Leonardi S, Mahaffey KW, White HD, Gibson CM, Stone GW, Steg GW, Hamm CW, Price MJ, Todd M, Dietrich M, Gallup D, Liu T, Skerjanec S, Harrington RA, Bhatt DL.

Am Heart J. 2012 May;163(5):768-776.e2. doi: 10.1016/j.ahj.2012.02.018.

PMID:
22607853
8.

Platelet inhibition with cangrelor in patients undergoing PCI.

Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL.

N Engl J Med. 2009 Dec 10;361(24):2318-29. doi: 10.1056/NEJMoa0908628. Epub .

9.

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.

Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, Clegg J, Stankowski JE, Grogan DR, Harrington RA, Emanuelsson H, Weaver WD.

Am Heart J. 2006 Mar;151(3):689.e1-689.e10.

PMID:
16504633
10.

Platelet inhibition with cangrelor.

Lippi G, Franchini M, Favaloro EJ.

N Engl J Med. 2010 Mar 18;362(11):1049; author reply 1049. No abstract available.

PMID:
20301798
11.

P >0.05 not equal equivalent or noninferior.

Massel D.

Am J Cardiol. 2005 Oct 1;96(7):1035. No abstract available.

PMID:
16188541
12.

Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge.

Serebruany VL, Pokov AN, Fortmann SD, DiNicolantonio JJ.

Thromb Haemost. 2014 Jan;111(1):3-7. doi: 10.1160/TH13-08-0631. Epub 2013 Nov 28.

PMID:
24285121
13.

Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.

Faxon DP.

Nat Rev Cardiol. 2010 Mar;7(3):124-5. doi: 10.1038/nrcardio.2009.247. No abstract available. Erratum in: Nat Rev Cardiol. 2010 May;7(5):242.

PMID:
20179718
14.

Is it naive to load only clopidogrel-naive patients prior to PCI?

Massberg S, Kastrati A.

Eur Heart J. 2010 Jun;31(11):1298-300. doi: 10.1093/eurheartj/ehq082. Epub 2010 Apr 2. No abstract available.

15.

[ADP receptor blockers: new insights in the therapy and prophylaxis of ischemic heart disease].

Gassanov N, Caglayan E, Erdmann E, Er F.

Dtsch Med Wochenschr. 2011 Jul;136(27):1433-7. doi: 10.1055/s-0031-1281533. Epub 2011 Jun 28. Review. German.

PMID:
21713722
16.

Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.

Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, Shaburishvili T, Huber K, Prats J, Liu T, Harrington RA, Becker RC.

J Thromb Thrombolysis. 2012 Jul;34(1):44-55. doi: 10.1007/s11239-012-0737-3.

PMID:
22569899
17.

Cangrelor: a new CHAMPION for percutaneous coronary intervention.

Mehta SR.

Lancet. 2013 Dec 14;382(9909):1960-2. doi: 10.1016/S0140-6736(13)61840-1. Epub 2013 Sep 3. No abstract available.

PMID:
24011550
18.

Unraveling questions surrounding clopidogrel resistance and stent thrombosis: one less snag.

Moliterno DJ, Campbell CL.

J Am Coll Cardiol. 2007 Jun 19;49(24):2318-9. Epub 2007 Jun 4. No abstract available.

19.

Intravenous platelet blockade with cangrelor during PCI.

Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA; CHAMPION PLATFORM Investigators.

N Engl J Med. 2009 Dec 10;361(24):2330-41. doi: 10.1056/NEJMoa0908629. Epub .

20.
Items per page

Supplemental Content

Write to the Help Desk